Shareholders back reverse split and equity plan expansion as dilution persists at Jupiter Neurosciences

summarizeSummary

Jupiter Neurosciences shareholders approved a reverse stock split and a 5.25 million share increase to its equity plan. The company also disclosed ongoing dilution from its SEPA financing, with $1.5M in convertible notes still outstanding.

check_boxKey Events · Corporate Governance and Compliance · JUNS

• Reverse Stock Split Approved

  Stockholders approved a reverse split at a ratio between 1:10 and 1:100, with the board authorized to determine the exact ratio and timing. This is intended to regain Nasdaq compliance.

• Equity Plan Increased by 5.25M Shares

  Shareholders approved an amendment to the 2025 Equity Incentive Plan, adding 5.25 million shares. This increases potential dilution and may be used for employee retention or compensation.

• SEPA Financing Update Reveals Ongoing Dilution

  Approximately $1.5 million principal of convertible notes remains outstanding under the SEPA. To date, 12.5 million shares have been issued to Yorkville for net proceeds of only $4.1 million, reflecting deep discount conversions.

• Director Elections and Auditor Ratification

  All seven director nominees were elected, and Cherry Bekaert LLC was ratified as the independent auditor for fiscal year 2026.

auto_awesomeAnalysis · JUNS · Life Sciences

At the annual meeting, stockholders greenlit a reverse split ranging from 1:10 to 1:100 and a 5.25 million share increase to the equity incentive plan, equipping the board with tools to tackle Nasdaq delisting and retain talent. The filing also discloses that $1.5 million of convertible notes remain outstanding under the SEPA, with 12.5 million shares already issued for just $4.1 million in net proceeds — a deeply dilutive financing pattern that continues to weigh on the stock.